| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PD 153035 | CTRPv2 | pan-cancer | AAC | 0.25 | 2e-07 |
| mRNA | lapatinib | CTRPv2 | pan-cancer | AAC | 0.23 | 3e-07 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.32 | 4e-07 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | 0.21 | 4e-07 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.32 | 7e-07 |
| mRNA | austocystin d | CTRPv2 | pan-cancer | AAC | 0.21 | 7e-07 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.31 | 3e-06 |
| mRNA | neratinib | CTRPv2 | pan-cancer | AAC | 0.19 | 4e-06 |
| mRNA | GSK269962A | GDSC1000 | pan-cancer | AAC | -0.19 | 6e-06 |
| mRNA | TW 37 | GDSC1000 | pan-cancer | AAC | -0.18 | 2e-05 |